BioRestorative Therapies, Inc.

Equities

BRTX

US0906556065

Biotechnology & Medical Research

Delayed Nasdaq 10:45:23 2024-03-28 am EDT 5-day change 1st Jan Change
1.404 USD +0.80% Intraday chart for BioRestorative Therapies, Inc. +5.55% -19.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting CI
Top Midday Decliners MT
Top Premarket Decliners MT
BioRestorative Therapies Reports Positive Results From Lumbar Disc Treatment Candidate Trial; Shares Rise MT
BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Lower Late Afternoon MT
Sector Update: Health Care Stocks Mixed Monday Afternoon MT
Sector Update: Health Care MT
BioRestorative Therapies Shares Rise After Shareholder Broadrick Dale Boosts Stake MT
Biorestorative Therapies Enters into Supply Agreement with Evolutionary Biologics CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
BioRestorative Therapies Secures New York State License to Operate as Tissue Bank MT
Biorestorative Therapies Inc. Receives License from New York State CI
BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding CI
BioRestorative Therapies Says Lumbar Disc Disease Treatment Recommended to Continue Phase 2 Trial MT
BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100 CI
BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program CI
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial CI
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100 CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BioRestorative Therapies Hires Advisory Firm to Expand Drug Candidate Indication Pipeline MT
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX 100 CI
Chart BioRestorative Therapies, Inc.
More charts
BioRestorative Therapies, Inc. is a clinical-stage company engaged in developing therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells (MSCs), collected from the patient's bone marrow. BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat)-derived stem cells (BADSC) to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.393 USD
Average target price
12.5 USD
Spread / Average Target
+797.54%
Consensus
  1. Stock
  2. Equities
  3. Stock BioRestorative Therapies, Inc. - Nasdaq
  4. News BioRestorative Therapies, Inc.
  5. BioRestorative Therapies Files 10 Patent Applications for Chronic Lumbar Disc Disease Treatment; Shares Rise